Beyond the Pitch
Rev1 Founders’ Lunch | The Business of Hope: Taking a Groundbreaking Treatment to Market
Milo Biotechnology works to develop therapies to increase muscle strength and prevent muscle atrophy. These therapies provide individuals affected by Muscular Dystrophy a greater chance to live a normal life, and more importantly, is providing them and their families with hope.
Al Hawkins Co-Founded Milo Biotechnology, a Cleveland, OH based company, in January 2012, based on technology exclusively licensed from Nationwide Children’s Hospital in Columbus, Ohio. Milo is mid-clinical testing and has established clinical proof of concept in two muscular dystrophy indications. Prior to his role with Milo, Al served as VP of Business Development and an initial employee at BioMotiv and also Co-Founded gene therapy company Abeona Therapeutics.
Join us as Hawkins shares his experience building Milo Biotechnology, working with individuals affected with neuromuscular diseases, and how, through these therapies, he is able to enhance the quality of life for those affected.
Rev1’s Founders’ Lunch series features first-hand insights into the triumphs, trials, and tribulations of Rev1 company founding teams. Each luncheon will feature a founding story and tips on a topic, plus delicious food from a local eatery and optional guided tours of the Rev1 Labs facility.
Search Our Blog
Get startup tips and resources delivered directly to your inbox.
Tips for turning a concept into a company
From honing your pitch to getting your first customer
How and where to get the cash you need to grow
The Hard Stuff
How to navigate hiring, taxes, legal and more
The Network Effect
Making the right connections at the right time
The news and trends that matter to you
Rev1 News & Events
The latest buzz and networking opportunities